



iJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 Issue: IV Month of publication: April 2025

DOI: <https://doi.org/10.22214/ijraset.2025.69870>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Monoclonal Antibodies for Targeting Drug Delivery System

Ms. Harshada Pramod Gaikwad¹, Ms. Rekha kolpe², Mr. Nitin Gawai³, Ms. Srushti Santosh Ingale⁴
B.Pharmacy Department, Mahadev Kanchan College of Pharmaceutical Educational Research, Uruli kanchan , Pune,
Maharashtra, India

Abstract: *The remarkable specificity and capacity to identify distinct antigens expressed on sickle cell shave made monoclonal antibodies (mAbs) aground-breaking development in the field of targeted medication delivery systems. A specific and localized therapy can be by conjugating mAbs with therapeutic substance including chemotherapeutics, poisons, radionuclides, or nanoparticles. This reduces off-target effects and increases effectiveness. These antibody- drug conjugates or ADCs are frequently utilized to treat infectious illness, autoimmune conditions and malignancies .The therapeutic potential of mAbs further enhanced by their integration with Nano-carrier technologies which enhance drug stability, bio-distribution and controlled release. For their wider clinical success, issues including immunogenicity, high production cost and anti-gene variability must be resolved despite their norms potential. This study highlights the revolutionary influence of monoclonal based drug delivery on contemporary medicine by examining its processes, developments, uses and constraints.*

Keywords: *Monoclonal antibodies, target drug delivery , antibody-drug conjugates , nano-carriers , immunotherapy , tumor targeting , antibody engineering , cancer therapy , precision medicine , biologics.*

I. INTRODUCTION

Developments in immunology and molecular biology have transformed the field of therapeutic medication development in recent decades. Using monoclonal antibodies (mAbs) for targeted medication delivery is one of the most innovative and promising developments. These synthetic compounds are engineered to attach selectively to certain antigens that are frequently overexpressed on the surface of sick cells, including cancerous cells. A fantastic chance to deliver therapeutic drugs directly to diseased locations while reducing off-target effects on healthy tissues is presented by this precision targeting capacity^[1-2].

Because of their great specificity, affinity, and capacity to be modified to transport a variety of payloads, including as chemotherapeutic drugs, radioactive isotopes, toxins, and nanoparticles, monoclonal antibodies have drawn a lot of interest in the development of targeted drug delivery systems (TDDS). Their use is found in many different diseases, but the most studied is cancer, which is followed by autoimmune, infectious, and inflammatory disorders^[3-4].

In the realm of modern medicine, monoclonal antibodies (mAbs) have emerged as one of the most revolutionary advancements for targeted therapy. These laboratory-produced molecules are engineered to recognize and bind with high specificity to unique antigens found on the surface of certain cells. Their high affinity and selectivity allow them to serve as excellent carriers in drug delivery systems, particularly for conditions such as cancer, autoimmune diseases, and infectious disorders.

The concept of targeted drug delivery aims to direct therapeutic agents specifically to the site of action, minimizing off-target effects and improving therapeutic efficacy. Traditional drug delivery systems often suffer from systemic toxicity and poor bioavailability. Monoclonal antibodies, due to their antigen-specific binding, can navigate biological systems with precision, delivering drugs directly to affected cells while sparing healthy tissues. Because monoclonal antibodies may identify molecular markers that are either exclusively or excessively expressed on sick cells, they offer a clear advantage in medication administration. For example , many cancerous tumour overexpress surface receptors such as CD20 or HER2. By acting as homing devices and directing cytotoxic medications or nanoparticles to the tumour site, antibodies made to bind these markers can improve the effectiveness of treatment. The creation of antibody-drug conjugates (ADCs) is one of the most popular approaches in antibody based delivery. These are complex compounds that have a monoclonal antibody chemically bound to a cytotoxic agent. The conjugate is internalized into the cell after attaching to the target antigen, and the medication is then released to start working. This method raises the drug's concentration at the target site while lowering systemic toxicity. In addition to oncology, autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis are being studied using mAb-based delivery systems. In these conditions, monoclonal antibodies can be coupled with immunosuppressive or anti-inflammatory drugs to improve their localization to inflammatory tissues and increase the tolerance of treatment.

The uses of mAbs have been significantly extended by recent scientific advancements. The improved pharmacokinetics, decreased immunogenicity, and increased tissue penetration of bispecific antibodies, nanobodies, and antibody fragments are being studied. These next-generation antibody forms show promise for creating delivery systems that are even more efficient and patient-friendly. All things considered, monoclonal antibodies are revolutionizing medication delivery by offering a strong and adaptable platform for targeted therapy. It is anticipated that their application will increase in a variety of therapeutic domains with continued study and development. In addition to improving therapeutic precision, the incorporation of mAbs with cutting-edge drug delivery methods opens the door for personalized medicine.

II. BACKGROUND AND EVOLUTION OF MONOCLONAL ANTIBODIES

The idea of monoclonal antibodies was first introduced by Kohler and Milstein in 1975. They used hybridoma technology to create homogenous antibody populations from a single B-cell clone. The creation of mAbs with a single specificity and consistent characteristics that are appropriate for therapeutic use was made possible by this discovery^[5].

The first monoclonal antibody generations were from murine (mouse) sources, which frequently caused immunological responses in people (human anti-mouse antibodies, or HAMA response). Since then, recombinant DNA technologies, phage display, and transgenic mice have been used to create chimeric, humanized, and completely human monoclonal antibodies in order to get around this restriction^[6]. In addition to binding to particular cellular targets, monoclonal antibodies have been modified over time to be conjugated with cytotoxic drugs (antibody-drug conjugates, or ADCs), radioisotopes (radio immunotherapy), enzymes (for prodrug activation), or encapsulated into Nano carriers for improved therapeutic delivery in addition to these other uses^[7].

When Georges Köhler and César Milstein initially devised a technique to create identical (monoclonal) antibodies from a single clone of B cells in 1975, monoclonal antibody (mAb) technology was born. They produced hybridomas that could continuously produce particular antibodies by combining immortal myeloma cells with B cells that produce antibodies. In addition to paving the way for a new age in immunology and therapeutic innovation, this ground-breaking discovery earned them the 1984 Nobel Prize in Physiology or Medicine. Originally, murine (mouse-derived) cells were employed to create monoclonal antibodies, which frequently resulted in immunogenic reactions in humans, also referred to as the human anti-mouse antibody (HAMA) response. In order to get around this, researchers created chimeric and humanized antibodies, which drastically decreased negative immunological reactions by substituting human components for the majority of the mouse protein structure. Ultimately, a significant breakthrough in therapeutic safety and effectiveness was made possible by the creation of fully human monoclonal antibodies using phage display technologies and transgenic mice.

III. TARGETING MECHANISM IN DRUG DELIVERY

The capacity of a drug delivery system to deliver the therapeutic agent at the appropriate location, at the appropriate time, and in the appropriate concentration is critical to its effectiveness. Active targeting is made possible by monoclonal antibodies, which bind specifically to antigens or receptors that are overexpressed on target cells. Tumor-associated antigens (TAAs), viral proteins, inflammatory indicators, and tissue-specific receptors are a few examples of these antigens.

By identifying and binding with great specificity to antigens found on the surface of sick cells, such as cancerous or infected cells, monoclonal antibodies (mAbs) enable targeted drug delivery. This selective recognition protects healthy tissues from off-target effects by directing the therapeutic agent—typically conjugated to the antibody—specifically to the site of pathology. The antibody component directs the medication to its target by acting as a homing device. This method reduces systemic toxicity and increases treatment efficacy, which is especially important in chemotherapy because non-specific damage to healthy cells frequently results in serious side effects.

Passive and active targeting strategies are two more subcategories of targeting systems. The enhanced permeability and retention (EPR) effect, which occurs when macromolecules like antibodies preferentially aggregate in tumor tissue as a result of leaky vasculature and inadequate lymphatic drainage, is used in passive targeting. Active targeting, on the other hand, uses monoclonal antibodies (mAbs) that attach to particular cell surface receptors, such EGFR, CD20, or HER2, to promote intracellular drug delivery and receptor-mediated endocytosis. In addition to enhancing drug localization, these sophisticated targeting techniques enable the modification of biological pathways, which enhances treatment results across a range of illnesses, especially in immunotherapy and oncology.

A monoclonal antibody acts as a guided missile, guiding the payload to the illness site when it is attached to a medication or a carrier system. Systemic toxicity, a frequent problem with traditional medicines, is decreased and therapeutic effectiveness is increased with this antibody-targeted delivery^[8-10].

Key mechanisms of action include:

- 1) Antibody-Dependent Cellular Cytotoxicity (ADCC)
- 2) Complement-Dependent Cytotoxicity (CDC)
- 3) Apoptosis induction
- 4) Blocking of receptor-ligand interaction
- 5) Internalization and release of the conjugated drug^[11-12]

IV. TYPES OF MONOCLONAL ANTIBODY DRUG CONJUGATES (ADCs)

Antibody-Drug Conjugates (ADCs) are an important class of antibody-based delivery systems. These consist of:

- 1) A monoclonal antibody (targeting moiety)
- 2) A cytotoxic agent (payload)
- 3) A linker (to connect the two)

The linker plays a crucial role in ensuring the drug is stable in circulation but is released in the intracellular environment of the target cell, usually in acidic lysosomes or by enzyme-triggered mechanisms.

Examples of FDA-approved ADCs include:

- Trastuzumab emtansine (Kadcyla) for HER2-positive breast cancer
- Brentuximab vedotin (Adcetris) for Hodgkin lymphoma
- Inotuzumab ozogamicin for acute lymphoblastic leukemia^[13-14]

V. NANOPARTICLES AND MABS IN DRUG DELIVERY

mAbs improve the targeting capabilities of medication delivery systems based on nanoparticles. Monoclonal antibodies can be used to surface-functionalize Nano carriers such as liposomes, micelles, dendrimers, and polymeric nanoparticles, enabling:

Site-specific drug buildup, Restricted release of drugs, Enhanced bioavailability and pharmacokinetics, Decreased toxicity and immunogenicity

For example, in HER2-positive breast cancer, liposomal doxorubicin coupled with anti-HER2 mAbs has demonstrated enhanced effectiveness^[15-16].

VI. APPLICATIONS IN ONCOLOGY AND BEYOND

Cancer treatment remains the most prominent field of mAb-based targeted delivery. Monoclonal antibodies are used for:

- 1) Direct tumor cell killing
- 2) Delivery of cytotoxic drugs to tumor sites
- 3) Inhibiting angiogenesis (e.g., bevacizumab against VEGF) □ Immune checkpoint blockade (e.g., nivolumab, pembrolizumab)^[17-18] Beyond oncology, mAbs are now being explored in:
- 4) Rheumatoid arthritis (e.g., tocilizumab, adalimumab)
- 5) Psoriasis
- 6) Inflammatory bowel diseases
- 7) Viral infections (e.g., palivizumab for RSV)
- 8) Neurodegenerative disorders (e.g., aducanumab in Alzheimer's)^[19-20]

VII. CHALLENGES IN MONOCLONAL ANTIBODY DRUG DELIVERY

Despite the promising potential, several challenges hinder the widespread adoption of mAb-targeted drug delivery systems:

- 1) High production cost and complexity
- 2) Stability and shelf-life of conjugates
- 3) Immunogenic reactions and allergic responses
- 4) Difficulty in achieving optimal pharmacokinetics and bio distribution
- 5) Tumor heterogeneity and antigen escape mechanisms

Addressing these challenges requires continuous research in antibody engineering, drug conjugation techniques, biomarker identification, and formulation strategies^[21-22].

VIII. CHALLENGES & FUTURE SCOPE OF STUDY

Thanks to developments in antibody engineering, nanotechnology, and personalized medicine, monoclonal antibodies have a very bright future in targeted medication delivery. The development of more accurate, effective, and patient-specific treatment systems is expected to be greatly aided by mAbs. New developments including nanobody technology, bispecific antibodies, and antibody fragments (Fab, scFv) have the potential to increase tissue penetration, decrease immunogenicity, and increase targeting precision. Additionally, mAbs might transform therapy results for neurological, autoimmune, and cancer conditions when combined with smart carriers like exosomes, stimuli-responsive nanoparticles, or CRISPR delivery platforms^[23-24].

But there are important issues that need to be resolved. Accessibility on a big scale is restricted by high production costs and intricate manufacturing procedures. Clinical safety and effectiveness issues are raised by immunogenic responses, antibody-drug conjugate (ADC) instability, and variations in antigen expression. Furthermore, the therapeutic effect is diminished by tumor heterogeneity, antigen escape mechanisms, and restricted penetration into solid tumors. Focus must continue to be placed on ensuring uniform pharmacokinetics, effective intracellular drug release, and combating multidrug resistance^[25-26]. Cost-effective technology, regulatory assistance, and multidisciplinary research are necessary to fully realize the potential of delivery systems based on monoclonal antibodies. The transition of targeted therapy from a specialized treatment to a common therapeutic strategy will require sustained innovation and co-operation^[27-28].

IX. CONCLUSION

The high specificity and capacity to deliver therapeutic compounds precisely to disease locations while reducing systemic toxicity, monoclonal antibodies are an effective tool in targeted drug delivery systems. In several therapeutic fields, particularly cancer, their combination with nanotechnology and cutting-edge carrier platforms has greatly increased therapy efficacy. Despite promising clinical results, the sector continues to encounter significant obstacles, including as variable antigen expression, difficult manufacturing, and immunogenic reactions. Their use and accessibility will be further increased by upcoming advancements that concentrate on tailored antibody forms, economical manufacturing, and enhanced targeting techniques. All things considered, medication delivery by monoclonal antibodies represents a major development in precision and personalized medicine.

REFERENCES

- [1] Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. *Nat Rev Drug Discovery* 2018;17(3):197–223.
- [2] Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody–drug conjugates. *Nat Rev Drug Discov*. 2017;16(5):315–337.
- [3] Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. *Br J Pharmacol*. 2009;157(2):220–233.
- [4] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. *Nat Rev Clin Oncol*. 2010;7(11):653–664.
- [5] Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. *Biosci Rep*. 2015;35(4):e00225.
- [6] Kontermann RE. Strategies for extended serum half-life of protein therapeutics. *Curr Opin Biotechnol*. 2011;22(6):868–876.
- [7] Lambert JM, Berkenblit A. Antibody–drug conjugates for cancer treatment. *Annu Rev Med*. 2018;69:191–207.
- [8] Adair BM, Love R. Nanoparticulate technologies for the delivery of biologics. *Pharm Res*. 2012;29(3):714–726.
- [9] Strohl WR. Current progress in innovative engineered antibodies. *Protein Cell*. 2015;6(8):563–577.
- [10] Thomas A, Teicher BA, Hassan R. Antibody–drug conjugates for cancer therapy. *Lancet Oncol*. 2016;17(6):e254–e262.
- [11] Tiwari G, Tiwari R, Sriwastaw B, Bhati L, Pandey S, Bannerjee SK. Drug delivery systems: An updated review. *Int J Pharm Investig*. 2012;2(1):2–11.
- [12] Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nat Rev Immunol*. 2010;10(5):317–327.
- [13] Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. *Blood*. 2016;127(1):53–61.
- [14] Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. *Nat Biotechnol*. 2005;23(9):1137–1146.
- [15] Kaplon H, Reichert JM. Antibodies to watch in 2019. *mAbs*. 2019; 11(2):219–238.
- [16] Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. *Drug Discov Today Technol*. 2016;21–22:75–83.
- [17] Müller D, Kontermann RE, Binder M. Bispecific antibodies: new therapeutic modalities. *Drugs*. 2021;81(2):125–157.
- [18] Zolot RS, Basu S, Million RP. Antibody–drug conjugates. *Nat Rev Drug Discov*. 2013;12(4):259–260.
- [19] Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS. Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. *Clin Cancer Res*. 2019;25(18):5441–5448.
- [20] Allen TM, Cullis PR. Liposomal drug delivery system: from concept to clinical applications. *Adv antages of Drug Delivery Rev*. 2013; 65(1): 36–48.
- [21] Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. *Med Princ Pract*. 2017;26(4):302–311.
- [22] Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. *Pharmacol Ther*. 2018;181: 126–142.
- [23] Hafeez U, Gan HK, Scott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. *Curr Opin Pharmacol*. 2020;52:1–10.
- [24] Jain S, Hirst DG, O'Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. *Br J Radiol*. 2012;85(1010):101–113.
- [25] Deng R, Jin F, Pramanik A, et al. Monoclonal antibody-mediated delivery of therapeutic agents for cancer treatment. *Drug Deliv*. 2018;25(1):1–14.



- [26] Banerjee S, Bhunia D. Recent advancements of monoclonal antibodies and bispecifics in solid tumor therapy. *Biomed Pharmacother.* 2022;149: 112806.
- [27] Van der Neut Kolfchoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. *Science.* 2007;317(5844):1554–1557.
- [28] Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. *Annu Rev Med.* 2013;64:15–29.
- [29] Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. *Nat Rev Cancer.* 2012;12(4):278–287.
- [30] Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. *J Nucl Med.* 2008;49(11):1735–1738.
- [31] Reichert JM. Metrics for antibody therapeutics development. *MAbs.* 2010;2(6):695–700.
- [32] Natarajan A, Mayer AT, Reeves RE, Gano J, Gambhir SS. Development of novel immunoconjugates for cancer imaging. *Curr Opin Chem Biol.* 2017; 39:57–65.
- [33] Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Damen CA, den Dunnen WF, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-EGFR nanobody. *Mol Imaging.* 2012;11(1):33–46.
- [34] Xu L, Anchordoquy TJ. Drug delivery trends in clinical trials and translational medicine: an analysis of ClinicalTrials.gov. *Int J Nanomedicine.* 2011;6: 1121–1126.
- [35] Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A Biparatopic HER2-targeting Antibody–Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-targeted Therapy. *Cancer Cell.* 2016;29(1):117–129.
- [36] Cuesta AM, Sánchez-Martín D, Sanz L, Bonet J, Compte M, Kremer L, et al. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. *PLoS One.* 2009;4(6):e5381.
- [37] Casi G, Neri D. Antibody–drug conjugates: basic concepts, examples and future perspectives. *Control Release.* 2012; 161(2):422–428.
- [38] Kratz F. Albumin as a drug carrier: design of pro-drugs, drug conjugates and nanoparticles. *J Control Release.* 2008;132(3):171–183.
- [39] Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advance and challenges *Pharmacol Ther.* 2013;138(3):452–469.
- [40] Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. *Cancer Res.* 2009;69(12):4941–4944.



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)